New Webinar


Catch COVID-19

-Improve your triage

Sign up to view webinar recording

View recording
New Webinar - View recording

Publications about suPAR

suPAR Monograph

On the basis of more than 600 published articles on suPAR in PubMed, a suPAR Monograph has been written.
Here you can find a short summary of the research done on suPAR within 12 groups of disease areas and see how the suPAR level is affected within each kind of disease.
The summary of each disease area is also found under Clinical Use.

Please find the suPAR Monograph here:

suPAR Monograph (English, June 2021)
suPAR Monograph (Spanish, May 2019)

See all publications in PubMed

Find your specific area of expertise and see all publications about suPAR in PubMed that are  relevant to you.

Examples of major studies about suPAR

“Association Between Elevated suPAR, a New Biomarker of Inflammation, and Accelerated Aging”, published in the Journals of Gerontology in July 2020.

The study shows that high suPAR levels were associated with an accelerated pace of biological aging across various organ systems, older facial appearance, and signs of older brain age. Participants with higher suPAR levels also showed decline in physical and cognitive function from childhood to adulthood compared to those with lower suPAR. Improvements of health habits between ages 38 and 45 were associated with less steep increases of suPAR levels over those years.

These findings support the utility of suPAR in studying the role of chronic inflammation in aging and functional decline.

Read the full article here

“Combining National Early Warning Score With Soluble Urokinase Plasminogen Activator Receptor (suPAR) Improves Risk Prediction in Acute Medical Patients: A Registry-Based Cohort Study”, published in Critical Care in December 2018.

The National Early Warning Score (NEWS) and suPAR were both connected to risk of in-hospital-, 30-day and 90-day mortality in acute medical patients. The suPAR level increased with increasing NEWS, and high suPAR independently predicted risk of mortality across different NEWS scores.

This means that suPAR adds prognostic value to NEWS, particularly in patients without clinical signs of deterioration. Patients with low NEWS but high suPAR levels had a life expectancy that can be compared to those with high NEWS scores.

The addition of suPAR to NEWS thus significantly improves risk prediction of both low- and high-risk acute medical patients.

Read the full open access article here

“Circulating soluble urokinase plasminogen activator receptor predicts cancer, cardiovascular disease, diabetes and mortality in the general population”, published in the Journal of Internal Medicine in September 2010.

The results of this observational study show that elevated suPAR levels were associated with increased risk of developing cancer, CVS, T2D and with a shorter life expectancy. suPAR was more strongly associated with cancer, CVD and mortality in men than in women, as well as in younger rather than in older individuals. These associations were robust even after adjustment for other known risk factors for these diseases.

The authors conclude that the use of this early warning inflammatory biomarker in standard screening procedures could improve the prediction of mortality and these major diseases.

Read the full article here


published suPAR studies in leading medical journals

The suPARnostic® brand consists of the following 3 products:

Photo of The suPARnostic® Quick Triage kit

Quick Triage

A Point of Care Solution

Photo of suPARnostic® TurbiLatex


For Automated Systems

Photo of suPARnostic® ELISA


Clinical and Research

Would you like to know more?

If you have any questions regarding our products or business, write to us here

Thank you!

You'll hear from us shortly.

An error occured!

Please try again, or contact us by e-mail if the problem persist.

Sign up for our newsletter

By signing up for our newsletter you will receive the latest news about our products.

Thank you!

You'll hear from us shortly.

An error occured!

Please try again, or contact us by e-mail if the problem persist.

suPARnostic® by ViroGates